Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Cited by (983)

Items 601–700 of 983

1. Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients
   Bin Jia, Peiyi Xia, Junqiang Dong, Wenhao Feng, Wenjia Wang, Enjie Liu, Guozhong Jiang, Yanru Qin · 2023 · Frontiers in Oncology
2. USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
   Dexin Yang, Yuqin Feng, Haohua Lu, Kelie Chen, Jinming Xu, Peiwei Li, Tianru Wang, Dajing Xia, Yihua Wu · 2023 · Journal of Zhejiang University SCIENCE B
3. Genomic features and its potential implication in bone oligometastatic NSCLC
   Rongxin Liao, Guangming Yi, Lu Shen, Xiaoyue Zhang, Zaicheng Xu, Yuan Peng, Zhenzhou Yang · 2023 · BMC Pulmonary Medicine
4. Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma
   Feng Li, Shuaibo Wang, Yaru Wang, Zhuoheng Lv, Donghui Jin, Hang Yi, Li Fu, Suokai Zhai, Ting Xiao, Yousheng Mao · 2023 · Frontiers in Immunology
5. Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report
   Zhe Zhu, Pei-Lin Dai, Shuai Han, Enming Qiu, Yu Wang, Li Zhou · 2023 · Frontiers in Oncology
6. Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
   Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto et al. · 2023 · OncoTargets and Therapy
7. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
   Parneet Kaur Cheema, Shantanu Otto Banerji, Normand Blais, Quincy Siu-Chung Chu, Rosalyn Anne Juergens, Natasha B. Leighl, Adrian Gerold Sacher, Brandon S. Sheffield, Stephanie Leann Snow, Mark David Vincent et al. · 2023 · Current Oncology
8. Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes
   Enrique Caballé‐Perez, Norma Hernández‐Pedro, Maritza Ramos-Ramírez, Pedro Barrios‐Bernal, Eunice Romero-Núñez, José Lucio-Lozada, Santiago Ávila‐Ríos, Gustavo Reyes‐Terán, Andrés Felipe Cardona, Oscar G. Arrieta · 2023 · Clinical & Translational Oncology
9. Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach
   Jingtao Wei, Ke Ji, Yue Zhang, Ji Zhang, Xiaojiang Wu, Xin Ji, Kai Zhou, Xuesong Yang, Hongfeng Lu, Anqiang Wang et al. · 2023 · Cellular Oncology
10. The association of genomic alterations with PD‐L1 expression in Chinese patients with EGFR / ALK wild‐type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy
    Fangfang Liu, Xuemei Zhang, Mengyao Lu, Chun Liu, Xiaodong Zhang, Qian Chu, Yuan Chen, Peng Zhang · 2024 · Cancer Medicine
11. First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis.
    Xiao-Jian Wang, Jia-Zhou Lin, Shu-Han Yu, Sheng-Xi Wu, He-San Luo, Zesen Du, Xu-Yuan Li · 2019 · Immunotherapy
12. [Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].
    Lei Liu, Suju Wei · 2018 · Europe PMC (PubMed Central)
13. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma
    Weiyin Lin, Anqi Lin, Zhefu Li, Chaozheng Zhou, Chufeng Chen, Boliang Chen, Qingwen Lyu, Jian Zhang, Peng Luo · 2020 · Biomedicine & Pharmacotherapy
14. Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?
    Francesco Tarantini, Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Giorgina Specchia, Pellegrino Musto, Francesco Albano · 2021 · Cancers
15. Efficacy and safety of immune checkpoint blockade in patients with Li-Fraumeni syndrome
    Bottosso, Michele, Verret, Benjamin, Caron, Olivier, Hamzaoui, Nadim, Pasmant, Eric, Danlos, Francois-Xavier, Boudou-Rouquette, Pascaline, Srikaran, Arunya, Blons, Hélène, Guarneri, Valentina et al. · 2024 · JCO Precision Oncology
16. Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
    Yuanhang Wang, Kelei Zhao, Jingjing Zhang, Xiaohan Yuan, Yanting Liu, Jinghang Zhang, Ping Lu, Min Zhang · 2024 · The Clinical Respiratory Journal
17. Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes
    Hanie Abolfathi, Manal Kordahi, Victoria E. S. Armero, Andréanne Gagné, Patrice Desmeules, Michèle Orain, Pierre Fiset, Dominique K. Boudreau, Nathalie Gaudreault, Fabien Claude Lamaze et al. · 2025 · Lung Cancer
18. Integrative proteomic characterization of human lung adenocarcinoma with KRAS G12 mutations reveals molecular pathogenesis
    Shi, Xinyu, Hu, Liling, Huang, Yongshi, Zhang, Mei-Fang, Ying, Xingfeng, Yuan, Xiaoyi, Wen, Nengqiao, Lu, Jiangli, Zou, Hanchen, Tan, Xiaohui et al. · 2026 · Journal of Advanced Research
19. Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
    Deborah Di-Xin Zhou, Sarah J. Lord, Frank P. Y. Lin, Wendy A. Cooper, Milita Zaheed, Robert John Simes, Thomas John, Chee Khoon Lee · 2025 · Lung Cancer
20. A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma
    Xiaonan Zhang, Simin Min, Yifan Yang, Dushan Ding, Qicai Li, Saisai Liu, Tao Tao, Ming Zhang, Baiqing Li, Shidi Zhao et al. · 2022 · Frontiers in Immunology
21. Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer
    Nikita Dutta, Anna Rohlin, Ella Äng Eklund, Maria K. Magnusson, Frida Nilsson, Levent M. Akyürek, Per Torstensson, Volkan I. Sayin, Anna Lundgren, Andreas Hallqvist et al. · 2023 · Frontiers in Oncology
22. Expression Profile and Gene Regulation Network of NUSAP1 in Pan Cancers Based on Integrated Bioinformatics Analysis
    Xiaodi Zhu, Yuting Wu, Liwei Liao, Wenqi Huang, Yuan Lu, Jihong Huang, Yongzhong Zhan, Laiyu Liu · 2023 · International Journal of General Medicine
23. Fusing WGCNA and Machine Learning for Immune-Related Gene Prognostic Index in Lung Adenocarcinoma: Precision Prognosis, Tumor Microenvironment Profiling, and Biomarker Discovery
    Jiaming He, Tiankuo Luan, Gang Zhao, Yingxue Yang · 2023 · Journal of Inflammation Research
24. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study
    Tadahiro Kuribayashi, Kadoaki Ohashi, Kazuya Nishii, Kiichiro Ninomiya, Yukari Tsubata, Nobuhisa Ishikawa, Masahiro Kodani, Nobuhiro Kanaji, Masahiro Yamasaki, Kazunori Fujitaka et al. · 2024 · Journal of Cancer Research and Clinical Oncology
25. Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB-ALK rearrangement and KRAS G12C mutation by sintilimab combined with anlotinib
    Nana Huang, Tianhao Qu, Chunxia Zhang, Jia Li · 2024 · Frontiers in Oncology
26. In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors
    Cecilia Pesini, Laura Artal, Jorge Paúl Bernal, Diego Sánchez‐Martínez, Julián Pardo, Ariel Ramírez-Labrada · 2024 · OncoImmunology
27. Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis
    Caroline-Claudia Erhart, Marco Cefalì, Dylan Mangan, Benjamin Kasenda, Luicano Wannesson · 2024 · Swiss Medical Weekly
28. A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer
    Bohao Zhang, Haozhe Zhang, Yanru Qin · 2025 · Frontiers in Bioscience-Landmark
29. Time-sequential change in immune-related gene expression after irradiation in glioblastoma: next-generation sequencing analysis
    Yi‐Jun Kim, Kwangsoo Kim, Soo Yeon Seo, Juyeon Yu, Il Han Kim, Hak Jae Kim, Chul‐Kee Park, Kye Hwa Lee, Junjeong Choi, Myung Seon Song et al. · 2021 · Animal Cells and Systems
30. Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non–Small-Cell Lung Cancer
    Sukhmani Kaur Padda, Jacqueline V. Aredo, Shireen Vali, Neeraj K. Singh, Sumanth M. Vasista, Ansu Kumar, Joel W. Neal, Taher Abbasi, Heather A. Wakelee · 2021 · JCO Precision Oncology
31. The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo
    Briana B Rackley, Chang-Soo Seong, Evan J. Kiely, Rebecca E. Parker, Manali Rupji, Bhakti Dwivedi, John M. Heddleston, W. Giang, Neil R. Anthony, Teng‐Leong Chew et al. · 2021 · Communications Biology
32. Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China
    Xiao Han, Jun Guo, Xiaoyong Tang, Hui Zhu, Dongyuan Zhu, Xiqin Zhang, Xiangjiao Meng, Ying Hua, Zhongtang Wang, Yan Zhang et al. · 2022 · Journal of Cancer Research and Clinical Oncology
33. Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes
    Rongchang Zhao, Dan Ding, Yan Ding, Rongbo Han, Xiujuan Wang, Chunrong Zhu · 2022 · Frontiers in Genetics
34. Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
    Yadong Wang, Ling Peng, Ming Zhao, Yuanyuan Xiong, Jianchao Xue, Bowen Li, Zhicheng Huang, Xinyu Liu, Xiaoying Yang, Yang Song et al. · 2022 · Translational Lung Cancer Research
35. Serendipitous synergism – an exceptional response to treatment with pembrolizumab in the course of a natural immunovirotherapy: a case report and review of the literature
    Lara M. Khoury, Kimberly M. Burcher, Ronald T. Ng, Alexander H. Song, Mark J. Chang, Elena Gavrila, Chance H. Bloomer, Mac Robinson, Brian E. Kouri, Joshua D. Waltonen et al. · 2022 · Therapeutic Advances in Medical Oncology
36. Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma
    Peng Zhang, Wenmiao Wang, Lei Liu, HouQiang Li, Xinyu Sha, Silin Wang, Zhanghao Huang, Youlang Zhou, Jiahai Shi · 2022 · Scientific Reports
37. Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer
    Rongxin Liao, Kehong Chen, Jinjin Li, Hengqiu He, Guangming Yi, Mingfeng Huang, Rongrong Chen, Lu Hua Shen, Xiaoyue Zhang, Zaicheng Xu et al. · 2023 · Cancer Research and Treatment
38. Comprehensive analysis of the role of a four-gene signature based on EMT in the prognosis, immunity, and treatment of lung squamous cell carcinoma
    Feng Li, Hui Wang, Can Wang, Yun Li, Jing‐Yan Song, Keyi Fan, Chao Li, Quan-Lin Ma, Qi Yu, Shuangping Zhang · 2023 · Aging
39. Characterization of somatic mutation-associated microenvironment signatures in acute myeloid leukemia patients based on TCGA analysis
    Jun Wang, Feng‐Ting Dao, Lu Yang, Ya‐Zhen Qin · 2020 · Scientific Reports
40. Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma
    Lu Yang, Jing Zhang, Yane Song, Guangjian Yang, Haiyan Xu, Junling Li, Lei Guo, Xin Li, Xinying Shi, Beibei Mao et al. · 2020 · Translational Oncology
41. Antiangiogenesis Combined with Immunotherapy to Treat Advanced Small-Cell Carcinoma of the Esophagus Resistant to Chemotherapy: According to the Guidance of Next-Generation Sequencing
    Man Jiang, Xiaochun Zhang · 2021 · OncoTargets and Therapy
42. Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
    Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli et al. · 2021 · Critical Reviews in Oncology/Hematology
43. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations
    Wei Li, Hong Mei Wu, Xuewen Xu, Yange Zhang · 2021 · Aging
44. Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
    Wenbo Qi, Dayong Xi, Yuping Bai, Le Liu, Yanling Ma, Zhenyu Yin, Hao Chen · 2023 · Frontiers in Pharmacology
45. The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer
    Takayuki Honda, Katsutoshi Seto, Satoshi Endo, Akira Takemoto, Kousuke Tanimoto, Masashi Kobayashi, Masatake Kitano, Rie Sakakibara, Takahiro Mitsumura, Hironori Ishibashi et al. · 2023 · Cancer Medicine
46. Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation
    Jianfeng Peng, Xianguang Zhao, Kaikai Zhao, Xiangjiao Meng · 2021 · Frontiers in Oncology
47. Annotated test-retest dataset of lung cancer CT scan images reconstructed at multiple imaging parameters
    Binsheng Zhao, Laurent Dercle, Hao Yang, Gregory J. Riely, Mark G. Kris, Lawrence Howard Schwartz · 2024 · Scientific Data
48. RETRACTED ARTICLE: Novel prognostic biomarkers in small cell lung cancer reveal mutational signatures, genomic mutations, and immune implications
    Yuting Li, Chen Song, Haijun Wang, Wenyu Di, Yangyang Chen, Yuanyuan Hu, Peiheng Li, Jie Chen, Yanfeng Ren, Jing Gong et al. · 2025 · Scientific Reports · Retracted
49. Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status—A Real-World Analysis in Patients With Advanced NSCLC
    David John Cantor, Halla Sayed Nimeiri, Leora Horn, Matthew West, Rotem Ben‐Shachar, Iker Huerga, Jyoti D. Patel, Charu Aggarwal · 2025 · Clinical Lung Cancer
50. Integrating STING activation with programmed death-ligand 1 inhibition: Novel approaches for cancer treatment
    Hossein Khorramdelazad, Reyhaneh Arfaei, Pegah Yaraghi, Armin Boroumand, Abbas Kheyri, Zahra Shirzad, Farzaneh Kheiri, Vahid Bagheri · 2026 · Critical Reviews in Oncology/Hematology
51. Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies
    H. Helena Wu, Sarah Leng, David D. Eisenstat, Consolato Maria Sergi, Roger P. Leng · 2026 · Cellular & Molecular Biology Letters
52. Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
    Zi-Tao Liu, Junting Shen, Yujie Lei, Yunchao Huang, Guangqiang Zhao, Chenghong Zheng, Xi Wang, Yutian Wang, Long Chen, Zixuan Li et al. · 2023 · BMC Cancer
53. Identification of tumor heterogeneity associated with KRAS/TP53 co-mutation status in lung adenocarcinoma based on single-cell RNA sequencing
    Ying-Hui Ye · 2024 · American Journal of Cancer Research
54. Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy
    Guomin Gu, Chunling Liu, Xiaodan Zhu, Yan Yang, Shuming Song, Yan Zhao, Gang Sun · 2024 · Journal of Cancer Research and Clinical Oncology
55. STOX1 Isoform A Promotes Proliferation and Progression of Hepatocellular Carcinoma by Dual Mechanisms of Transcriptionally Upregulation of Cyclin B1 and Activation of ROS‐Dependent PTEN/AKT1 Signaling
    Chunlin Jiang, Chong Wang, Jian Ao, Yangping Liu, Fengjie Sun, Wangpan Shi, Zeyi Guo, Yanping Wu, Luxiang Gan, Meimei Wu et al. · 2025 · Cancer Medicine
56. The Expression Pattern of Ferroptosis-Related Genes in Colon Adenocarcinoma: Highly Correlated to Tumor Microenvironment Characteristics
    Jie Liu, Hui Li, Shen Zhao, Rongbo Lin, Jiaqing Yu, Nanfeng Fan · 2022 · Frontiers in Genetics
57. Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer
    Liping Zhu, Dafu Ye, Tianyu Lei, Jie Wu, Wei Wang, Bin Xu · 2022 · Expert Reviews in Molecular Medicine
58. [Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)].
    2020 · PubMed Central
59. Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma
    Jialiang Cai, Suiyi Wu, Feng Zhang, Zhi Dai · 2022 · Frontiers in Immunology
60. PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer
    Zhixuan Ren, Li Wang, Chaohui Leng · 2023 · Aging
61. Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
    Yingmei Wen, Yi Dong, Lina Yi, Guifang Yang, Mengxia Xiao, Qingqing Li, Chen Zhao, Dafu Ye, Yi Yao · 2023 · Frontiers in Oncology
62. NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Qingyuan Huang, Hang Cao, Qianlan Yao, Xiaoyan Zhou, Hang Li, Qianming Bai, Hong Hu · 2023 · ImmunoTargets and Therapy
63. Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
    Dan Zhao, Haiqing Li, Isa Mambetsariev, Tamara Mirzapoiazova, Chen Chen, Jeremy Fricke, Deric L. Wheeler, Leonidas D. Arvanitis, Raju K. Pillai, Michelle Afkhami et al. · 2024 · npj Precision Oncology
64. Association of TP53 Mutation Status and Sex with Clinical Outcome in Non–Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study
    Songji Choi, Se Hyun Kim, Sejoon Lee, Jeongmin Seo, Min-Su Kang, Eun Hee Jung, Sang‐A Kim, Koung Jin Suh, Ji Yun Lee, Ji‐Won Kim et al. · 2024 · Cancer Research and Treatment
65. PD-L1 and Other Immunological Diagnosis Tools
    Nicolás A. Giraldo, Janis Marie Taube · 2017 · Springer eBooks
66. Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
    Shui Liu, Shuai Geng, Ning Shi, Lili Zhang, Wenxin Xue, Yiwen Helen Li, Kai Jiang · 2022 · Frontiers in Pharmacology
67. Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases
    Jiaquan Mao, Chunguang Yang, Sheng Xin, Kai Cui, Zheng Liu, Tao Wang, Zhiquan Hu, Shaogang Wang, Jihong Liu, Xiaodong Song et al. · 2022 · Frontiers in Medicine
68. Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
    Min Wang, Ji Li, Shuhui Xu, Yuying Li, Jiatong Li, Jinming Yu, Xiaoyong Tang, Hui Zhu · 2022 · Cancer Medicine
69. RAS: Circuitry and therapeutic targeting
    Gagandeep Singh, Neelam Thakur, Umesh Kumar · 2022 · Cellular Signalling
70. First-line immunotherapy in non-small cell lung cancer: how to select and where to go
    Andrea Mogavero, Ornella Cantale, Veronica Mollica, Shobana Anpalakhan, Alfredo Addeo, Giannis Mountzios, Alex Friedlaender, Ravindran Kanesvaran, Silvia Novello, Giuseppe Luigi Banna · 2023 · Expert Review of Respiratory Medicine
71. Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study
    Sokbom Kang, Ye Lee Yu, Soo Y. Cho, Seog-Yun Park · 2020 · European Journal of Cancer
72. Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score
    Si‐Yang Maggie Liu, Hao Sun, Jiaying Zhou, Jia‐Tao Zhang, Kai Yin, Zhihong Chen, Jian Su, Xu‐Chao Zhang, Jin‐Ji Yang, Qing Hua Zhou et al. · 2021 · Translational Oncology
73. [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].
    2021 · PubMed Central
74. A transferrable and interpretable multiple instance learning model for microsatellite instability prediction based on histopathology images
    Rui Cao, Fan Yang, Si-Cong Ma, Li Liu, Yan Li, Dehua Wu, Yu Zhao, Tongxin Wang, Weijia Lu, Wei-Jing Cai et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
75. The Prognostic Value of TP53 Alteration in Patients with Head and Neck Squamous Cell Carcinoma Receiving Immunotherapy
    Chao Jiang, Xuanchen Zhou, Jie Han, Zhiyong Yue, Butuo Li · 2022 · The Oncologist
76. Beyond the Tissue: Unlocking NSCLC Treatment Potential Through Liquid Biopsy
    Milica Kontić, Mihailo Stjepanović, Filip Marković · 2025 · Genes
77. Radiotherapy disrupts ferroptosis tolerance by reducing DNMT1 levels and uncouples STING silencing in LKB1-deficient lung tumors
    Yan-Pei Zhang, Fei-Fei Wu, Ze-Nan Wu, Yan Li, Jia-Qi Chen, Xiao-Ting Cai, Xin-Yi Quan, Zi-Xuan Rong, Ze-Qin Guo, Zhijiao Duan et al. · 2026 · Free Radical Biology and Medicine
78. Tumor Cells as Architects of Immune Refractoriness: Dismantling Intrinsic Programs of Tumor Cells for Clinical Translation
    Hyo-Jung Lee, Eunho Cho, Kwon‐Ho Song, Tae Woo Kim · 2026 · Immune Network
79. Izalontamab Brengitecan in Locally Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study
    Huaqiang Zhou, Hongyun Zhao, Xue Hou, Yongsheng Wang, Zhiyong He, Yongsheng Li, Yuxiang Ma, Yu-Heng Zhao, Yan Huang, Likun Chen et al. · 2026 · Journal of Clinical Oncology
80. Clinical characteristics, outcomes and prognostic factors in KRAS mutant lung cancers: experience from a tertiary care cancer center in India
    Vanita Noronha, Laboni Sarkar, Vijay Patil, Nandini Sharrel Menon, Minit Jalan Shah, Akash Pawar, Oindrila Roy Chowdhury, Omshree Anil Shetty, Anuradha Chougule, Pratik Chandrani et al. · 2024 · ecancermedicalscience
81. Network pharmacology and molecular docking analysis on the mechanism of Wensan tincture in the treatment of pulmonary nodules: A review
    Jinzhi Zhang, Jingqi Yang, Guangxi Li · 2024 · Medicine
82. Identification of novel gene-based risk score for prognosis in prostate cancer
    Huangwei Huang, Xia Sun, Peixin Li, Haoxin Cai, Lei Xu, Benkang Shi, Sifeng Qu · 2025 · Scientific Reports
83. Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China
    Guomin Gu, Bo Yu, Hua Wan, Suqiong Lu, Xiaodan Zhu, Yan Zhao, Yujing Fuxi, Chunling Liu · 2022 · OncoTargets and Therapy
84. Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy
    Jiayue Qiu, Xiangmei Li, Yalan He, Qian Wang, Ji Li, Jiashuo Wu, Ying Jiang, Junwei Han · 2022 · Journal of Translational Medicine
85. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma
    Yongzhao Li, Qidong Yang, Yaqin Liu, Huan Yi, Yongzhi Ju, Guoyan Qi · 2023 · Investigational New Drugs
86. Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC
    Yu Fu, Weichen Duan, Ran Xu, Jiajia Chen · 2023 · Frontiers in Immunology
87. The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer
    Ziyun Shen, Meixin Teng, Lu Han, Dongliang Bian, Jing Zhang, Xinsheng Zhu, Yang Qing, Shiqi Hu, Yan Chen, Wangchao Yao et al. · 2023 · Cancer Immunology Immunotherapy
88. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer
    Lei Wang, Meng Diao, Zheng Zhang, Minlin Jiang, Shifu Chen, Deping Zhao, Zhenguo Liu, Caicun Zhou · 2023 · Lung Cancer
89. Evaluating targeted therapies in older patients with TP53 -mutated AML
    Jean M.G. Sabile, Ronan T. Swords, Jeffrey W Tyner · 2024 · Leukemia & lymphoma/Leukemia and lymphoma
90. FAM3D regulation of head and neck squamous cell carcinoma behaviour through the EMT pathway
    Zheng Zhou, Xiaotian Hu, Chengpu Zhao, Jiafeng Wang, Hongfeng He · 2024 · Oral Diseases
91. Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC
    Hui Li, Jingjing Liu, Liang Zhang, Yu Xu, Xinyue Wang, Shaowei Lan, Peng Lei Cui, Guoqiang Wang, Shangli Cai, Ying Cheng · 2024 · Journal for ImmunoTherapy of Cancer
92. Circulating Tumor Cell-Free DNA as Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: The CORELAB Experience
    Stefania Gelmini, Adele Calabri, Irene Mancini, Camilla Comin, Valeria Pasini, Marco Banini, Vieri Scotti, Pamela Pinzani · 2025 · International Journal of Molecular Sciences
93. Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution
    Yusaku Momoi, Shogo Kumagai, Hiroyoshi Nishikawa · 2025 · International Immunology
94. The Role of Nuclear Phosphoinositides in the p53-MDM2 Nexus
    Jeong Hyo Lee, Muhammad Khalil Salah, Xiangqin Chen, Nickolas Vladimir Kucherenko, Vincent L. Cryns, Richard Allen Anderson · 2025 · Cells
95. KRAS and Immune Checkpoint Inhibitors—Serendipity Raising Expectations
    Sacha I. Rothschild · 2019 · Journal of Thoracic Oncology
96. Targeted-Gene Sequencing and Bioinformatics Analysis of Patients with Pancreatic Mucoepidermoid Carcinoma: A Case Report and Literature Review
    Zhitao Chen, Lele Zhang, Jiacheng Huang, Chenchen Ding, Ting Zhang, Dalong Wan, Xue Liang · 2021 · OncoTargets and Therapy
97. The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
    Miriam Grazia Ferrara, Alessio Stefani, Sara Pilotto, Carmine Carbone, Emanuele Vita, Mariantonietta Di Salvatore, Ettore D’Argento, Ileana Sparagna, Federico Monaca, Giustina Valente et al. · 2021 · Frontiers in Oncology
98. Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer
    Yue Li, Chong Li, Ya Jiang, Xue Han, Sisi Liu, Xiuxiu Xu, Wanxiangfu Tang, Qiuxiang Ou, Hua Bao, Xue Wu et al. · 2022 · Journal of Oncology
99. Therapeutic Outcomes and Clinical Features of Advanced Non–Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study
    Giulia Mazzaschi, Fabiana Perrone, Roberta Minari, Michela Verzè, Cinzia Azzoni, Lorena Bottarelli, Monica Pluchino, Maria Pia Armillotta, Annalisa Ubaldi, Annalisa Altimari et al. · 2022 · Clinical Lung Cancer
100. Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer
     Chien‐Yu Lin, Ming‐Yin Shen, William Tzu‐Liang Chen, Chin‐An Yang · 2023 · Journal of Personalized Medicine